六福彩票

Information Hub

Clinical News

2019-12-30

A new targeted therapy for advanced gastrointestinal stromal tumors (GIST)

六福彩票Ripretinib is a novel tyrosine kinase inhibitor that was designed to target KIT and PDGFRα-mutated kinase. A phase III study (INVICTUS) showed that ripretinib improved PFS and OS compared with placebo in patients with GIST progressed with more than three

Source:

2019 ESMO congress

2019-12-30

Maintenance olaparib with bevacizumab improves progression-free Survival in patients with newly diagnosed ovarian cancer

六福彩票In phase 3 PAOLA-1 trial, olaparib plus bevacizumab as first-line maintenance therapy significantly prolongs the progression-free survival of ovarian cancer patients.

Source:

N Engl J Med & Annals of Oncology

2019-12-30

Neratinib ± fulvestrant was effective in patients with advanced breast cancer and HER2 mutations

The plasmaMATCH trial is a phase 2a, open-label, multicentre trial in patients with advanced breast cancer. The trial aims to evaluate whether certain genetic mutation identified through ctDNA could benefit patients from matched targeted treatments. In th

Source:

Wardley. SABCS 2019

2019-11-27

Co-occurring PIK3CA mutations in cis increase PI3K/AKT/mTOR signaling pathway activation and sensitivity to PI3Kα inhibitors in breast cancer

六福彩票A study showed the mechanism of activating PI3K/AKT/mTOR signaling by double PIK3CA mutations in cis. Furthermore, a retrospective analysis of a phase III study (SANDPIPER) showed that co-occurring PIK3CA mutations were associated with clinical benefits i

Source:

六福彩票Science. 2019

2019-11-27

Ivosidenib significantly improved the survival of cholangiocarcinoma patients who had a mutation in IDH1

六福彩票In phase 3 ClarIDHy trial, ivosidenib showed a strong efficacy in treating cholangiocarcinoma patients who had an IDH1 mutation. Ivosidenib extended both the OS and PFS significantly compared to the control group.

Source:

Annals of Oncology (2019)

2019-11-27

Cabozantinib prolonged PFS and improved ORR compared to sunitinib among renal cell carcinoma patients, especially in those with MET alteration

六福彩票There is ongoing debate on which treatment is optimal for patients with advanced renal cell carcinoma. The phase II CABOSUN trial demonstrated cabozantinib improved response compared to sunitinib. The MET status was associated with greater benefit.

Source:

Oncologist. 2019

2019-10-24

Olaparib showed clinical benefits in heavily pretreated mCRPC with homologous recombination repair (HRR) gene mutations

A phase III study (PROfound) showed that homologous recombination repair (HRR) gene mutations were associated with greater clinical benefits compared with physician’s choice of enzalutamide or abiraterone plus prednisone in heavily pretreated mCRPC patien

Source:

ESMO Congress 2019

2019-10-24

Veliparib demonstrated clinical benefits in patients with ovarian cancer

In the phase 3 VELIA trial, veliparib showed a good therapeutic effect when added to standard first-line chemotherapy and continued as maintenance therapy in ovarian cancer.

Source:

六福彩票N Engl J Med. 2019

2019-10-24

Pemigatinib demonstrates clinical activity in second-line FGFR2 fusion cholangiocarcinoma

According to findings from the phase 2 FIGHT-202 clinical trial presented at ESMO 2019, pemigatinib, a selective inhibitor of FGFR1, 2, and 3, showed clinical benefits in previously treated advanced or metastatic cholangiocarcinoma (CCA) patients with an

Source:

六福彩票2019 ESMO Congress

2019-09-23

Genetic alterations associated with immunotherapy response in advanced NSCLC

六福彩票The results of a phase III study (MYSTIC) showed that ARID1A mutation were associated with clinical benefits in patients received durvalumab plus tremelimumab combination therapy

Source:

WCLC 2019

火红彩票-首页 河南彩票-首页 智胜彩票-首页 乐福彩票-首页 网易彩票-首页 信发彩票-首页